Endlyz Therapeutics launches and unveils its portfolio of programmes targeting Parkinson’s disease
Endlyz Therapeutics officially emerges from stealth, unveiling its therapeutic pipeline of small molecule modulators targeting ATP13A2 and ATP10B to restore lysosomal function in Parkinson’s (PD) and other neurodegenerative diseases.
